April 3 (Reuters) - Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study. (Reporting by Sneha S K in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.66 USD | +0.68% | -0.84% | 0.00% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 451M | |
+15.58% | 121B | |
+16.60% | 110B | |
+17.73% | 25.93B | |
-24.33% | 19.27B | |
-19.35% | 16.01B | |
-17.95% | 15.66B | |
-48.32% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- Lenz Therapeutics' eye disease drugs meet main goal of late-stage study